

## **CRITICAL LIMB ISCHEMIA WESTERN EUROPE INDEX OF TABLES**

Table 1: Occlusion Types, Duration and Characteristics	12.
Table 2: Critical Limb Ischemia Risk Factors	13.
Table 3: Critical Limb Ischemia Comorbid Conditions Present in Patients Undergoing Revascularization	14.
Table 4: 2003 Prevalence of Diabetes and Impaired Glucose Tolerance in the Adult Population Age 20-79 in Western Europe and the United States	19.
Table 5: Western Europe 2010-2030 Peripheral Artery Disease and Critical Limb Ischemia Patient and Limb Prevalence	24.
Table 6: Western Europe Prevalence of Peripheral Artery Disease and Critical Limb Ischemia in the Adult Population	25.
Table 7: Germany 2010-2030 Number of People with PAD and CLI	26.
Table 8: Germany Population Age $\geq 65$ Glucose Status	27.
Table 9: Germany Population Age $\geq 65$ PAD Prevalence by Glucose Status	27.
Table 10: Germany Population Age $\geq 65$ CLI Prevalence in PAD by Glucose Status	27.
Table 11: Germany Population Age 45-64 Glucose Status	28.
Table 12: German Population Age 45-64 PAD Prevalence by Glucose Status	28.
Table 13: Germany Population Age 45-64 CLI Prevalence in PAD by Glucose Status	28.
Table 14: Germany Population Age 25-44 Glucose Status	29.
Table 15: Germany Population Age 25-44 PAD Prevalence by Glucose Status	29.
Table 16: Get ABI Trial Prevalence of PAD in the German Population Age 65 and Older	30.
Table 17: PAD Prevalence in getABI Study By Age and Glucose Status	30.
Table 18: Prevalence of Peripheral Arterial Disease by Age and Sex Heinz Nixdorf Recall Study Population	31.
Table 19: KORA Survey-Germany Comparison of Glucose Status by Sex in the 55-74 Age Group	32.
Table 20: Italy 2010-2030 Number of People with PAD and CLI	33.
Table 21: Italy Population Age $\geq 60$ Glucose Status by Age Group	34.

Table 22: Italy Population Age $\geq 60$ PAD Prevalence Categorized by Age Group and Glucose Status	34.
Table 23: Italy Population Age $\geq 60$ CLI Prevalence in PAD by Glucose Status	35.
Table 24: Italy Population Age 40-59 Glucose Status	35.
Table 25: Italy Population Age 40-59 PAD Prevalence by Glucose Status	36.
Table 26: Italy Population Age 40-59 CLI Prevalence in PAD by Glucose Status	36.
Table 27: Italy Population Age 20-39 Glucose Status	37.
Table 28: Italy Population Age 20-39 PAD Prevalence by Glucose Status	37.
Table 29: Spain 2010-2030 Number of People with PAD and CLI	38.
Table 30: Spain Population Age $\geq 65$ Glucose Status by Age Group and Sex	39.
Table 31: Spain Population Age $\geq 65$ PAD Prevalence by Glucose Status	40.
Table 32: Spain Population Age $\geq 65$ CLI Prevalence in PAD by Glucose Status	41.
Table 33: Spain Population Age 45-64 Glucose Status by Age Group and Sex	41.
Table 34: Spain Population Aged 45-64 PAD Prevalence by Glucose Status	42.
Table 35: Spain Population Age 45-64 CLI Prevalence in PAD by Glucose Status	42.
Table 36: Spain Population Age 25-44 Glucose Status	43.
Table 37: Spain Population Age 25-44 PAD Prevalence by Glucose Status	43.
Table 38: United Kingdom 2010-2030 Number of People with PAD and CLI	44.
Table 39: U.K. Population Age $\geq 65$ Glucose Status by Age Group and Sex	45.
Table 40: U.K. Population Age $\geq 65$ PAD Prevalence by Glucose Status	46.
Table 41: U.K. Population Age $\geq 65$ CLI Prevalence in PAD by Glucose Status	46.
Table 42: U.K. Population Age 45-64 Glucose Status by Age Group and Sex	47.
Table 43: U.K. Population Age 45-64 PAD Prevalence by Glucose Status	47.
Table 44: U.K. Population Age 45-64 CLI Prevalence in PAD by Glucose Status	48.
Table 45: U.K. Population Age 35-44 Glucose Status by Age and Sex	48.
Table 46: U.K. Population Age 35-44 PAD Prevalence by Glucose Status	48.

Table 47: OXVASC Incidence of Critical Limb Ischemia	49.
Table 48: France 2010-2030 Number of People with PAD and CLI	51.
Table 49: France Population Age $\geq$ 65 Glucose Status by Age Group	52.
Table 50: France Population Age $\geq$ 65 PAD Prevalence by Glucose Status	53.
Table 51: France Population Age $\geq$ 65 CLI Prevalence in PAD by Glucose Status	53.
Table 52: France Population Age 45-64 Glucose Status by Age Group	54.
Table 53: France Population Age 45-64 PAD Prevalence by Glucose Status	54.
Table 54: France Population Age 45-64 CLI Prevalence in PAD by Glucose Status	54.
Table 55: France Population Age 30-44 Glucose Status by Age Group	55.
Table 56: France Population Age 30-44 PAD Prevalence by Glucose Status	55.
Table 57: The Netherlands 2010-2030 Number of People with PAD and CLI	56.
Table 58: The Netherlands Population Age $\geq$ 60 Glucose Status by Age Group	57.
Table 59: The Hoorn Study PAD Prevalence by Age Group and Glucose Status	58.
Table 60: The Netherlands Population Age $\geq$ 60 CLI Prevalence in PAD by Glucose Status	58.
Table 61: The Netherlands Population Age 50-59 Glucose Status	59.
Table 62: The Hoorn Study PAD Prevalence by Age Group and Glucose Status	59.
Table 63: The Netherlands Population Age 50-59 CLI Prevalence in PAD by Glucose Status	60.
Table 64: The Netherlands Population Age 30-49 Glucose Status by Age Group	61.
Table 65: The Netherlands Population Age 30-49 PAD Prevalence by Glucose Status	61.
Table 66: Greece 2010-2030 Number of People with PAD and CLI	62.
Table 67: Greece Population Age $\geq$ 60 Glucose Status by Age Group and Sex	63.
Table 68: Greece Population Age $\geq$ 60 PAD Prevalence by Glucose Status	64.
Table 69: Greece Population Age $\geq$ 60 CLI Prevalence in PAD by Glucose Status	64.
Table 70: Greece Population Age 40-59 Glucose Status by Age Group and Sex	65.
Table 71: Greece Population Age 40-59 PAD Prevalence by Glucose Status	65.

Table 72: Greece Population Age 40-59 CLI Prevalence in PAD by Glucose Status	66.
Table 73: Greece Population Age 30-39 Glucose Status by Sex	66.
Table 74: Greece Population Age 30-39 PAD Prevalence by Glucose Status	66.
Table 75: Sweden 2010-2030 Number of People with PAD and CLI	67.
Table 76: Sweden Population Age $\geq 65$ Glucose Status by Age Group and Sex	68.
Table 77: Sweden Population Age $\geq 65$ PAD Prevalence by Glucose Status	69.
Table 78: Sweden Population Age $\geq 65$ CLI Prevalence in PAD by Glucose Status	69.
Table 79: Sweden Population Age 45-64 Glucose Status by Age group and Sex	70.
Table 80: Sweden Population Age 45-64 PAD Prevalence by Glucose Status	70.
Table 81: Sweden Population Age 45-64 CLI Prevalence in PAD by Glucose Status	71.
Table 82: Sweden Population Age 25-44 Glucose Status by Age Group and Sex	71.
Table 83: Sweden Population Age 25-44 PAD Prevalence by Glucose Status	71.
Table 84: Austria 2010-2030 Number of People with PAD and CLI	72.
Table 85: Austria Population Age $\geq 65$ Glucose Status	73.
Table 86: Austria Population Age $\geq 65$ PAD Prevalence by Glucose Status	73.
Table 87: Austria Population Age $\geq 65$ CLI Prevalence in PAD by Glucose Status	74.
Table 88: Austria Population Age 45-64 Glucose Status	74.
Table 89: Austria Population Age 45-64 PAD Prevalence by Glucose Status	74.
Table 90: Austria Population Age 45-64 CLI Prevalence in PAD by Glucose Status	75.
Table 91: Austria Population Age 25-44 Glucose Status	75.
Table 92: Austria Population Age 25-44 PAD Prevalence by Glucose Status	75.
Table 93: Switzerland 2010-2030 Number of People with PAD and CLI	76.
Table 94: Switzerland Population Age $\geq 65$ Glucose Status	77.
Table 95: Switzerland Population Age $\geq 65$ PAD Prevalence by Glucose Status	78.
Table 96: Switzerland Population Age $\geq 65$ CLI Prevalence in PAD by Glucose Status	78.

Table 97: Switzerland Population Age 45-64 Glucose Status	79.
Table 98: Switzerland Population Age 45-64 PAD Prevalence by Glucose Status	79.
Table 99: Switzerland Population Age 45-64 CLI Prevalence in PAD by Glucose Status	79.
Table 100: Switzerland Population Age 25-44 Glucose Status	80.
Table 101: Switzerland Population Age 25-44 PAD Prevalence by Glucose Status	80.
Table 102: Belgium 2010-2030 Number of People with PAD and CLI	81.
Table 103: Belgium Population Age $\geq 65$ Glucose Status by Age Group and Sex	82.
Table 104: Belgium Population Age $\geq 65$ PAD Prevalence by Glucose Status	83.
Table 105: Belgium Population Age $\geq 65$ CLI Prevalence in PAD by Glucose Status	83.
Table 106: Belgium Population Age 45-64 Glucose Status by Sex	83.
Table 107: Belgium Population Age 45-64 PAD Prevalence by Glucose Status	84.
Table 108: Belgium Population Age 45-64 CLI Prevalence in PAD by Glucose Status	84.
Table 109: Belgium Population Age 25-44 Glucose Status by Sex	85.
Table 110: Belgium Population Ages 25-44 PAD Prevalence by Glucose Status	85.
Table 111: Portugal 2010-2030 Number of People with PAD and CLI	86.
Table 112: Portugal Population Age $\geq 65$ Glucose Status by Age Group and Sex	87.
Table 113: Portugal Population Age $\geq 65$ PAD Prevalence by Glucose Status	87.
Table 114: Portugal Population Age $\geq 65$ CLI Prevalence in PAD by Glucose Status	88.
Table 115: Portugal Population Age 45-64 Glucose Status by Sex	88.
Table 116: Portugal Population Ages 45-64 PAD Prevalence by Glucose Status	88.
Table 117: Portugal Population Age 45-64 CLI Prevalence in PAD by Glucose Status	89.
Table 118: Portugal Population Age 25-44 Glucose Status by Sex	89.
Table 119: Portugal Population Age 25-44 PAD Prevalence by Glucose Status	89.
Table 120: Finland 2010-2030 Number of People with PAD and CLI	90.
Table 121: Finland Population Age $\geq 65$ Glucose Status by Sex	91.

Table 122: Finland Population Age $\geq$ 65 PAD Prevalence by Glucose Status	92.
Table 123: Finland Population Age $\geq$ 65 CLI Prevalence in PAD by Glucose Status	92.
Table 124: Finland Population Age 45-64 Glucose Status by Sex	93.
Table 125: Finland Population Age 45-64 PAD Prevalence by Glucose Status	93.
Table 126: Finland Population Age 45-64 CLI Prevalence in PAD by Glucose Status	93.
Table 127: Finland Population Age 25-44 Glucose Status by Sex	94.
Table 128: Finland Population Age 25-44 PAD Prevalence by Glucose Status	94.
Table 129: Denmark 2010-2030 Number of People with PAD and CLI	95.
Table 130: Denmark Population Age $\geq$ 65 Glucose Status by Age Group and Sex	96.
Table 131: Denmark Population Age $\geq$ 65 PAD Prevalence by Glucose Status	97.
Table 132: Denmark Population Age $\geq$ 65 CLI Prevalence in PAD by Glucose Status	97.
Table 133: Denmark Population Age 45-64 Glucose Status by Sex	97.
Table 134: Denmark Population Age 45-64 PAD Prevalence by Glucose Status	98.
Table 135: Denmark Population Ages 45-64 CLI Prevalence in PAD by Glucose Status	98.
Table 136: Denmark Population Age 25-44 Glucose Status by Sex	98.
Table 137: Denmark Population Age 25-44 PAD Prevalence by Glucose Status	99.
Table 138: Norway 2010-2030 Number of People with PAD and CLI	100.
Table 139: Norway Population Age $\geq$ 60 Glucose Status by Age Group and Sex	101.
Table 140: Norway Population Age $\geq$ 60 PAD Prevalence by Glucose Status	102.
Table 141: Norway Population Age $\geq$ 60 CLI Prevalence in PAD by Glucose Status	102.
Table 142: Norway Population Age 40-59 Glucose Status by Age Group and Sex	103.
Table 143: Norway Population Age 40-59 PAD Prevalence by Glucose Status	103.
Table 144: Norway Population Age 40-59 CLI Prevalence in PAD by Glucose Status	103.
Table 145: Norway Population Age 30-39 Glucose Status by Sex	104.
Table 146: Norway Population Age 30-39 PAD Prevalence by Glucose Status	104.

Table 147: Western Europe and the United States 2010 and 2030 Comparison of the Number of People with PAD and CLI	105.
Table 148: 2010-2030 Western Europe Critical Ischemia Market Potential According to the Ideal Treatment Pathway	106.
Table 149: Critical Limb Ischemia Ideal Treatment Pathway	107.
Table 150: 2010-2030 Western Europe Critical Limb Ischemia Revascularization Market in Patients and Limbs	109.
Table 151: 2010-2030 Western Europe Potential Endovascular Market in Number of Limbs	110.
Table 152: Western Europe Dollar Value of Potential Endovascular Market to Treat Critical Limb Ischemia Comparison of 2010, 2015, 2020, 2025 and 2030	111.
Table 153: 2010-2030 Critical Limb Ischemia Projected Market Impact of New Technology Maintaining Constant Share or Increasing Share	113.
Table 154: 2010-2030 Western Europe Potential Stent Market in Procedures and Dollars	114.
Table 155: 2010-2030 Western Europe Potential Bypass Market Primary and Redo Procedures in Number of Limbs	115.
Table 156: 2010-2030 Western Europe Potential Endovascular Market for Treatment of Chronic Total Occlusions in Critical Limb Ischemia	118.
Table 157: 2010-2030 Western Europe Critical Limb Ischemia Market Potential for Antihypertensives	120.
Table 158: 2010-2030 Western Europe Critical Limb Ischemia Market Potential for Antilipid Pharmaceuticals	121.
Table 159: 2010-2030 Western Europe Critical Limb Ischemia Market Potential for Antiplatelet Pharmaceuticals	122.
Table 160: 2010 Population of Fifteen Countries in Western Europe	125.

## **INDEX OF FIGURES**

Figure 1: 2010-2030 Projected Number of Primary Endovascular and Surgical Procedures 117.  
Assuming Endovascular and Surgical Market Shares Remain Constant

Figure 2: 2010-2030 Projected Number of Primary Endovascular and Surgical Procedures 118.  
Assuming Endovascular Increases Market Share to 85%